Commentary
Volume 7:02, 2024

Journal of Clinical Neurology and Neurosurgery

ISSN: 2684-6012 Open Access

Waldenstrom Macroglobulinemia Recurrence: Bing–Neel Syndrome Reappearance

Carpel Chopkhiats*

Department of Radiology, University of Michigan, Ann Arbor, MI 48109, USA

Introduction

Waldenström Macroglobulinemia (WM), a rare and indolent B-cell lymphoproliferative disorder characterized by the accumulation of lymphoplasmacytic cells in the bone marrow and monoclonal IgM paraproteinemia, poses unique challenges in its management and treatment due to its heterogeneity and potential for recurrence. One such rare complication of WM recurrence is Bing-Neel syndrome, an uncommon neurological manifestation characterized by the infiltration of malignant lymphoplasmacytic cells into the Central Nervous System (CNS), including the brain and spinal cord. This comprehensive discourse seeks to delve into the intricacies of Waldenström Macroglobulinemia recurrence, with a specific focus on the reappearance of Bing-Neel syndrome, encompassing an introduction to WM, its pathogenesis and clinical features, the phenomenon of recurrence, the enigmatic nature of Bing-Neel syndrome, diagnostic modalities, therapeutic approaches and avenues for future research [1].

Description

Waldenström Macroglobulinemia, first described by Jan G. Waldenström in 1944, represents a rare subtype of non-Hodgkin lymphoma characterized by the infiltration of lymphoplasmacytic cells into the bone marrow, leading to the production of monoclonal IgM paraprotein. The precise etiology of WM remains elusive, with genetic, environmental and immunological factors implicated in its pathogenesis. Most cases of WM are sporadic, although rare familial forms associated with inherited mutations in genes such as MYD88 and CXCR4 have been reported. Clinically, WM manifests with a spectrum of symptoms, including fatigue, weakness, lymphadenopathy, hepatosplenomegaly and peripheral neuropathy, attributable to the infiltration of tumor cells and the effects of monoclonal IgM on various organ systems. Despite advancements in the treatment of WM, including the advent of novel targeted therapies such as Bruton's Tyrosine Kinase (BTK) inhibitors and proteasome inhibitors, disease recurrence remains a significant challenge, particularly in patients with high-risk features such as advanced stage, refractory disease and adverse cytogenetic abnormalities. WM recurrence is often heralded by the reappearance of clinical symptoms, laboratory abnormalities and imaging findings indicative of disease progression, prompting the need for vigilant monitoring and early intervention. While the mechanisms underlying WM recurrence are multifactorial and incompletely understood, clonal evolution, acquisition of drug resistance and microenvironmental factors are thought to play pivotal roles in disease relapse and progression [2,3].

Bing-Neel syndrome represents a rare and enigmatic complication of WM recurrence characterized by the infiltration of malignant lymphoplasmacytic cells into the CNS, leading to a spectrum of neurological manifestations, including cognitive impairment, cranial nerve palsies, ataxia and seizures. The pathophysiology of Bing-Neel syndrome involves the migration of tumor cells across the blood-brain barrier, facilitated by chemokine receptors and adhesion molecules and their subsequent proliferation within the CNS microenvironment. The diagnosis of Bing-Neel syndrome poses a formidable challenge due to its rarity, nonspecific clinical presentation and the absence of characteristic imaging findings, necessitating a high index of suspicion and multimodal diagnostic approach, including cerebrospinal fluid analysis, neuroimaging and neurocognitive assessments. Management of Bing-Neel syndrome requires a multidisciplinary approach involving hematologists, neurologists and neuro-oncologists, aimed at achieving disease control, preserving neurological function and improving quality of life. Treatment strategies for Bing-Neel syndrome encompass a combination of systemic therapies targeting WM, including chemotherapy, immunotherapy and targeted agents and CNS-directed interventions such as intrathecal chemotherapy, radiation therapy and stem cell transplantation. However, optimal therapeutic regimens for Bing-Neel syndrome remain to be defined and further research is warranted to elucidate the underlying mechanisms of CNS involvement in WM and to develop novel therapeutic strategies targeting the CNS microenvironment [4,5].

Conclusion

In conclusion, Waldenström Macroglobulinemia recurrence, with its attendant complications such as Bing-Neel syndrome, represents a formidable clinical challenge requiring a comprehensive understanding of disease biology, vigilant monitoring and individualized therapeutic approaches. While significant progress has been made in the management of WM in recent years, including the development of novel targeted therapies, further research is needed to elucidate the mechanisms underlying disease recurrence and to identify biomarkers predictive of treatment response and prognosis. Moreover, collaborative efforts between clinicians, researchers and patient advocacy groups are essential for advancing our understanding of WM recurrence and improving outcomes for patients afflicted by this rare and complex hematological malignancy and its neurological sequelae.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Ly, K. Ina, Florian Fintelmann, Reza Forghani and Pamela W. Schaefer, et al. "Novel diagnostic approaches in Bing-Neel syndrome." *Clin Lymphoma Myeloma Leuk* 11 (2011): 180-183.
2. Fitsiori, Aikaterini, Luc-Matthieu Fornecker, Laurence Simon and Alexandros Karentzos, et al. "Imaging spectrum of Bing-Neel syndrome: How can a radiologist recognise this rare neurological complication of Waldenström's macroglobulinemia?." *Eur Radiol* 29 (2019): 102-114.

***Address for Correspondence:** Carpel Chopkhiats, Department of Radiology, University of Michigan, Ann Arbor, MI 48109, USA, E-mail: carpelchopkhiats@hotmail.com*

Received: 01 April, 2024, Manuscript No. jcnn-24-134962; **Editor Assigned:** 03 April, 2024, PreQC No. P-134962; **Reviewed:** 15 April, 2024, QC No. Q-134962; **Revised:** 20 April 2024, Manuscript No. R-134962; **Published:** 27 April, 2024, DOI: 10.37421/2684-6012.2024.7.222

3. Levine, T., A. Pestronk, J. Florence and M. T. Al-Lozi, et al. "Peripheral neuropathies in Waldenström's macroglobulinaemia." *J Neurol Neurosurg Psychiatry* 77 (2006): 224-228.

4. Kotsos, Dimitrios, Sofia Chatzileontiadou, Athanasia Apsemidou and Anna Xanthopoulou, et al. "Bing-Neel syndrome: real-life experience in personalized diagnostic approach and treatment." *Front Oncol* 12 (2022): 891052.

5. Drozd-Sokołowska, Joanna, Anna Waszczuk-Gajda, Magdalena Witkowska and Elżbieta Sienkiewicz, et al. "Bing-Neel syndrome, a rare presentation of Waldenström Macroglobulinemia-a multicenter report by the polish lymphoma research group." *J Clin Med* 11 (2022): 4447.

How to cite this article: Chopkhiats, Carpel. "Waldenstrom Macroglobulinemia Recurrence: Bing-Neel Syndrome Reappearance." *J Clin Neurol Neurosurg* 7 (2024): 222.